Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Menggang Yu

Showing results (151-160 of 176) with videos related to

Pageof 18
Sort By:
Ebiomedicine|December 13, 2024
Safety and toxicity of Iopofosine I 131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: results of a phase 1 single-centre, open-label, single-arm, dose escalation and dose expansion studyJustine Yang Bruce, Adam Burr, Randall J Kimple, et al.
Hematological Oncology|August 4, 2021
Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysisChristopher R D'Angelo, Walter Hanel, Yi Chen, et al.
NPJ Genomic Medicine|September 22, 2021
Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT SignaturesNicholas R Rydzewski, Erik Peterson, Joshua M Lang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial CancerMatthew D Galsky, Amir Mortazavi, Matthew I Milowsky, et al.
American Journal of Medical Genetics. Part A|April 6, 2011
Multiple increased osteoclast functions in individuals with neurofibromatosis type 1David A Stevenson, Jincheng Yan, Yongzheng He, et al.
Communications Biology|March 14, 2024
A platform-independent AI tumor lineage and site (ATLAS) classifierNicholas R Rydzewski, Yue Shi, Chenxuan Li, et al.
JAMA Oncology|September 23, 2021
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate CancerRahul Aggarwal, Nicholas R Rydzewski, Li Zhang, et al.
Journal of the National Cancer Institute|August 1, 2022
Surveillance Imaging vs Symptomatic Recurrence Detection and Survival in Stage II-III Breast Cancer (AFT-01)Jessica R Schumacher, Heather B Neuman, Menggang Yu, et al.
The Lancet. Oncology|October 17, 2016
Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysisShuang G Zhao, S Laura Chang, Daniel E Spratt, et al.
European Urology|December 18, 2017
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on OutcomesMatthew D Galsky, Huan Wang, Noah M Hahn, et al.
Pageof 18

Showing results (151-160 of 176) with videos related to

Sort By:
Pageof 18
Ebiomedicine|December 13, 2024
Safety and toxicity of Iopofosine I 131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: results of a phase 1 single-centre, open-label, single-arm, dose escalation and dose expansion studyJustine Yang Bruce, Adam Burr, Randall J Kimple, et al.
Hematological Oncology|August 4, 2021
Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysisChristopher R D'Angelo, Walter Hanel, Yi Chen, et al.
NPJ Genomic Medicine|September 22, 2021
Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT SignaturesNicholas R Rydzewski, Erik Peterson, Joshua M Lang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial CancerMatthew D Galsky, Amir Mortazavi, Matthew I Milowsky, et al.
American Journal of Medical Genetics. Part A|April 6, 2011
Multiple increased osteoclast functions in individuals with neurofibromatosis type 1David A Stevenson, Jincheng Yan, Yongzheng He, et al.
Communications Biology|March 14, 2024
A platform-independent AI tumor lineage and site (ATLAS) classifierNicholas R Rydzewski, Yue Shi, Chenxuan Li, et al.
JAMA Oncology|September 23, 2021
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate CancerRahul Aggarwal, Nicholas R Rydzewski, Li Zhang, et al.
Journal of the National Cancer Institute|August 1, 2022
Surveillance Imaging vs Symptomatic Recurrence Detection and Survival in Stage II-III Breast Cancer (AFT-01)Jessica R Schumacher, Heather B Neuman, Menggang Yu, et al.
The Lancet. Oncology|October 17, 2016
Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysisShuang G Zhao, S Laura Chang, Daniel E Spratt, et al.
European Urology|December 18, 2017
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on OutcomesMatthew D Galsky, Huan Wang, Noah M Hahn, et al.
Pageof 18